Centrum Med. Ostrobramska NZOZ Magodent

Warsaw 04-125

0 studies enrolling now · 1 studies all time

What they study most

Renal Cell Carcinoma

Studies at this site

• A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma — Completed